DGX - Quest Diagnostics Incorporated

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $220.57 DETAILS

Stock News

Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year?

Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.

May 26, 2026 06:40 AM • zacks.com

Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

May 21, 2026 08:31 AM • zacks.com

Quest Diagnostics Declares Quarterly Cash Dividend

SECAUCUS, N.J., May 19, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on July 22, 2026 to shareholders of record of Quest Diagnostics common stock on July 8, 2026.

May 19, 2026 12:37 PM • prnewswire.com

Is This the Right Time to Hold DGX Stock in Your Portfolio?

Quest Diagnostics gains from DIS growth, advanced diagnostics uptake and AI-driven efficiencies, though debt levels and healthcare reimbursement risks remain concerns.

May 19, 2026 06:30 AM • zacks.com

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.

May 14, 2026 10:22 AM • barrons.com

Bullish Quarterly Results: 3 Companies Raising Guidance

Guidance upgrades are generally among the most bullish announcements a company can make, signaling that the outlook is even better than previously expected.

May 07, 2026 03:45 PM • zacks.com

Quest Diagnostics: Updating Levels After Q1 Earnings

Quest Diagnostics delivered strong Q1 results with 9.2% revenue growth and 13% EPS growth, driving management to raise 2026 guidance. DGX's growth is fueled by advanced diagnostics, robust consumer and hospital channels, and efficiency gains from AI and automation. Key risks include margin pressure from lower-priced partnership volumes and potential Medicare reimbursement cuts under PAMA.

May 07, 2026 11:40 AM • seekingalpha.com

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

May 06, 2026 06:41 AM • zacks.com

Quest Diagnostics Prices $500 Million of Senior Notes

SECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the "Notes") under Quest Diagnostics' shelf registration statement.

Apr 27, 2026 12:10 PM • prnewswire.com

AEGON ASSET MANAGEMENT UK Plc Decreases Stake in Quest Diagnostics Incorporated $DGX

AEGON ASSET MANAGEMENT UK Plc cut its holdings in Quest Diagnostics Incorporated (NYSE: DGX) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,605 shares of the medical research company's stock after selling 27,786

Apr 25, 2026 11:09 PM • defenseworld.net

Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely

Quest Diagnostics delivered Q1 2026 revenue of $2.9 billion (+9.2% YoY) and EPS of $2.24 (+15.5% YoY), but shares dipped post-earnings. DGX maintains a strong core business with high barriers to entry, steady but unspectacular growth, and industry-leading market access. Forward P/E is ~19x and P/S

Apr 24, 2026 06:53 AM • seekingalpha.com

Quest Diagnostics Incorporated $DGX Stock Holdings Decreased by Cwm LLC

Cwm LLC lessened its position in Quest Diagnostics Incorporated (NYSE: DGX) by 28.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,950 shares of the medical research company's stock after selling 7,532 shares during the quarter. Cwm LLC's holdings in Quest

Apr 23, 2026 11:46 PM • defenseworld.net

Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Apr 22, 2026 06:51 AM • zacks.com

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings

Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday reported upbeat earnings for the first quarter on Tuesday.

Apr 22, 2026 06:27 AM • benzinga.com

Is Quest Diagnostics Inc (DGX) Overvalued After 4.5% Rally? GF Value Says Overvalued

On April 21, 2026, Quest Diagnostics Inc (DGX) shares rose 4.5% to a current price of $205.04. This move is part of a broader uptrend, with the stock experienci

Apr 21, 2026 01:53 PM • gurufocus.com

Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript

Apr 21, 2026 07:20 AM • seekingalpha.com

Quest Diagnostics' Q1 Earnings & Revenues Top Estimates, Stock Up

DGX posts Q1 2026 earnings and revenue beat, with adjusted EPS up 13% and shares rising in pre-market trading.

Apr 21, 2026 05:56 AM • zacks.com

Quest Diagnostics (DGX) Q1 Earnings and Revenues Top Estimates

Quest Diagnostics (DGX) came out with quarterly earnings of $2.5 per share, beating the Zacks Consensus Estimate of $2.37 per share. This compares to earnings of $2.21 per share a year ago.

Apr 21, 2026 04:56 AM • zacks.com

Quest Diagnostics raises full-year forecast, posts strong quarter on testing demand

Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing.

Apr 21, 2026 03:42 AM • reuters.com

Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted diluted EPS of $2.50, up 13.1% from 2025 Full year 2026 reported diluted EPS now expected to be between $9.58 and $9.78; and adjusted diluted EPS is expected to be between $10.63 and $10.83 SECAUCUS, N.J., April 21, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

Apr 21, 2026 02:47 AM • prnewswire.com